Minimed Group (STU:B8S) EBIT: €-154 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:B8S Minimed Group Inc STU:B8S
20 GF Score
Price €16.60
! 3 Warning Signs
View Full Analysis

What is Minimed Group EBIT?

Minimed Group STU:B8S 20 EBIT is €-154 Mil as of Apr. 2026. GuruFocus rates STU:B8S with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Minimed Group's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2026 was €-74 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2026 was €-154 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Minimed Group's annualized ROC % for the quarter that ended in Apr. 2026 was -8.95%. Minimed Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -37.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Minimed Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -3.35%.

Minimed Group  (STU:B8S) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Minimed Group's annualized ROC % for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=-297.54 * ( 1 - 0% )/( (3271.244 + 3380.67)/ 2 )
=-297.54/3325.957
=-8.95 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3695.893 - 416.139 - ( 8.51 - max(0, 592.296 - 942.908+8.51))
=3271.244

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3958.65 - 323.19 - ( 254.79 - max(0, 600.21 - 1152.54+254.79))
=3380.67

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Minimed Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-297.54/( ( (596.551 + max(351.463, 0)) + (607.905 + max(32.49, 0)) )/ 2 )
=-297.54/( ( 948.014 + 640.395 )/ 2 )
=-297.54/794.2045
=-37.46 %

where Working Capital is:

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(555.703 + 346.357 + 32.338) - (416.139 + 11.063 + 155.733)
=351.463

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(171 + 291.555 + 46.17) - (323.19 + 12.825 + 140.22)
=32.49

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Minimed Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2026 )
=-153.528/4577.439
=-3.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group EBIT Related Terms

Minimed Group EBIT Historical Data

* Premium members only.

The historical data trend for Minimed Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group EBIT Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25 Apr26
EBIT
-62.93 -56.85 29.37 -135.95

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26 Apr26
EBIT Get a 7-Day Free Trial 21.25 27.59 0.00 -79.14 -74.39

STU:B8S vs MMSI, NVST, STVN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Minimed Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minimed Group EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Minimed Group's EV-to-EBIT falls into.


STU:B8S
20GF Score
Minimed Group Inc STU:B8S
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-154 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-154 Mil mean?
Minimed Group (STU:B8S) has a EBIT of €-154 Mil as of Apr. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Minimed Group.
Is Minimed Group's EBIT too high?
Minimed Group's current EBIT is €-154 Mil. Overall, Minimed Group has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's EBIT compare to MMSI and NVST?
Minimed Group's EBIT of €-154 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Minimed Group. Minimed Group's current EBIT is €-154 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (STU:B8S) has a current EBIT of €-154 Mil. The current EBIT is €-154 Mil. Minimed Group's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Minimed Group (STU:B8S), the current EBIT is €-154 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges MMED:USA
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
20GF Score

Get the complete analysis for STU:B8S

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.60
Price